Blueprint Medicines Net Income

Blueprint Medicines (BPMC) currently reports a net income of $-160M as of March 2025. That compares with $-290M in the prior-year period — up 46.0% year over year. That is below the Healthcare sector average of $16B. Use the charts on this page to explore Blueprint Medicines's net income history and peer comparisons.

Blueprint Medicines's net income increased from $-290M to $-160M — a 46.0% year-over-year increase (period ending March 2025). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Blueprint Medicines's net income of $-160M is lower than the Healthcare sector average of $16B. That is roughly 101.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Blueprint Medicines reported $-160M in net income as of March 2025. That compares with $-290M in the prior-year period — up 46.0% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current net income of $-160M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $16B. From there, open related valuation or income-statement pages for Blueprint Medicines, and consider following BPMC for alerts when major investors trade the stock.